Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kirin (KNBWY) could produce exceptional returns because of its solid growth attributes.
Kirin (KNBWY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MD Michelle Dubey Yousif Capital Management LLC | 14,974 | $239,586.54 | $256,804.1 | $17,217.56 | 7.19% |
| Beverages Industry | Consumer Staples Sector | Yoshinori Isozaki CEO | OTC PINK Exchange | 497350207 CUSIP |
| JP Country | 31,934 Employees | 29 Jun 2026 Last Dividend | 3 Sep 2002 Last Split | - IPO Date |
Kirin Holdings Company, Limited is a diversified conglomerate with a broad spectrum of activities in the food and beverages, pharmaceuticals, and health science industries. With its headquarters in Tokyo, Japan, the company has evolved from its initial focus on brewing to encompass a wide range of consumer products and services. Founded in 1885 as Kirin Brewery Company, Limited, it embraced its current name in July 2007 to reflect its expanded business portfolio. Kirin Holdings is dedicated to providing high-quality products and services, leveraging its extensive research and development capabilities to meet the diverse needs of customers worldwide.
Kirin Holdings Company, Limited offers a diversified range of products and services across various sectors. These include: